[{"bbox": [114, 95, 1703, 1123], "category": "Table", "text": "<table><thead><tr><td>Results</td><td>Results Chain: Main expected results (max. 10)</td><td>Indicators: (at least one indicator per expected result)</td><td>Baselines (values and years)</td><td>Targets (values and years)</td><td>Sources of data</td><td>Assumptions</td></tr></thead><tbody><tr><td></td><td></td><td>3.4. Level of availability of epidemiological information both for research and for public awareness.</td><td></td><td></td><td></td><td></td></tr><tr><td>Output 1 related to Outcome 1</td><td>1.1. Improved and upgraded R&D Unit capable of researching, developing, producing active pharmaceutical ingredients (IPAs) and operating the characterization laboratory</td><td>1.1.1 Status of modernisation of R&D Unit of CIGB Mariel</td><td>1.1.1 Not modernized, equipment and technologies are obsolete in 2022</td><td>1.1.1 Modernized; equipment and technologies are up to date</td><td>1.1.1 Provisional and final certificates of acceptance of modernization and equipment by CIGB Mariel</td><td>CIGB Mariel is capable of further maintenance and upgrades and has a respective plan</td></tr><tr><td>Output 2 related to Outcome 1</td><td>1.2. Training of professionals at CIGB Mariel in state of the art production of IPAs and, international production and laboratory standards.</td><td>1.2.1 Status of the technology classroom created at the Mariel CIGB<br>1.2.2 Number of CIGB Mariel specialists trained to master the state-of-the-art production of IPAs and laboratory characterisation (** GERF 2.14)</td><td>1.2.1 CIGB Mariel does not have a tech classroom for the training of its specialists<br>1.2.2 ‘0’ by 2022.</td><td>1.2.1 CIGB Mariel has a modern and an accomplished tech classroom for training<br>1.2.2. TBD in the inception period</td><td>1.2.1 Provisional and final acceptance certificates by CIGB Mariel<br>1.2.2 Pre- and post-training tests, sign-in lists</td><td>CIGB Mariel has a plan for maintaining and keeping upgraded the tech classroom<br>Trained specialists stay at their job</td></tr><tr><td>Output 1 related to Outcome 2</td><td>2.1. Modernized NRA Control Laboratory with infrastructures, metrology and analytical capacities compatible with international standards for the development, production and control of medicines and biotechnological products.</td><td>2.1.1. Status of modernization of NRA Control Laboratories<br>2.1.2. Status of the Purchased reference materials (RMs) for work MR establishment.</td><td>2.1.1 None by 2022<br>2.1.2. To be defined in the inception period</td><td>2.1.1 The infrastructure is modernized, equipped with new equipment, including for metrological and analytical work<br>2.1.2. TBD in the inception period</td><td>2.1.1 Provisional and final acceptance by the NRA / CECMED<br>2.1.2. Reports on the collaborative studies carried out</td><td>The NRA / CECMED is supported with sufficient budgets and investments to further maintain and develop the Laboratory<br>It has a plan and respective funding for annually decided number of collaborative studies and new analytical methods</td></tr></tbody></table>"}, {"bbox": [1525, 1149, 1644, 1173], "category": "Page-footer", "text": "Page 15 of 24"}]